AIRLINK 65.20 Decreased By ▼ -0.70 (-1.06%)
BOP 5.57 Decreased By ▼ -0.12 (-2.11%)
CNERGY 4.56 Decreased By ▼ -0.09 (-1.94%)
DFML 24.52 Increased By ▲ 1.67 (7.31%)
DGKC 69.96 Decreased By ▼ -0.74 (-1.05%)
FCCL 20.30 Decreased By ▼ -0.05 (-0.25%)
FFBL 29.11 No Change ▼ 0.00 (0%)
FFL 9.83 Decreased By ▼ -0.10 (-1.01%)
GGL 10.01 Decreased By ▼ -0.07 (-0.69%)
HBL 114.25 Decreased By ▼ -1.00 (-0.87%)
HUBC 129.10 Decreased By ▼ -0.40 (-0.31%)
HUMNL 6.71 Increased By ▲ 0.01 (0.15%)
KEL 4.44 Increased By ▲ 0.06 (1.37%)
KOSM 4.89 Decreased By ▼ -0.13 (-2.59%)
MLCF 37.00 Increased By ▲ 0.04 (0.11%)
OGDC 132.30 Increased By ▲ 1.10 (0.84%)
PAEL 22.54 Increased By ▲ 0.06 (0.27%)
PIAA 25.89 Decreased By ▼ -0.41 (-1.56%)
PIBTL 6.60 Increased By ▲ 0.07 (1.07%)
PPL 112.85 Increased By ▲ 0.73 (0.65%)
PRL 29.41 Increased By ▲ 1.02 (3.59%)
PTC 15.24 Decreased By ▼ -0.87 (-5.4%)
SEARL 57.03 Decreased By ▼ -1.26 (-2.16%)
SNGP 66.45 Increased By ▲ 0.76 (1.16%)
SSGC 10.98 Decreased By ▼ -0.04 (-0.36%)
TELE 8.80 Decreased By ▼ -0.14 (-1.57%)
TPLP 11.70 Increased By ▲ 0.17 (1.47%)
TRG 68.62 Decreased By ▼ -0.62 (-0.9%)
UNITY 23.40 Decreased By ▼ -0.55 (-2.3%)
WTL 1.38 Increased By ▲ 0.03 (2.22%)
BR100 7,295 Decreased By -9.1 (-0.12%)
BR30 23,854 Decreased By -96 (-0.4%)
KSE100 70,290 Decreased By -43.2 (-0.06%)
KSE30 23,171 Increased By 50.4 (0.22%)

BRISBANE: Australian medical tech manufacturer Ellume said it had recalled almost 200,000 at-home Covid-19 tests in the United States over an increased chance of false positives.

Ellume's rapid at-home coronavirus test last year became the first to receive emergency use authorisation in the US.

The US Food and Drug Administration issued an alert Tuesday over the "potential for false positive results with certain lots of the Ellume COVID-19 Home Test, due to a recently identified manufacturing issue".

"Negative results do not appear to be affected by the manufacturing issue," the statement said.

"The FDA is working closely with Ellume to assess the company's additional manufacturing checks and other corrective steps to help ensure that the issue is resolved."

A spokesman for Ellume told AFP on Wednesday that 195,000 of the 3.5 million tests shipped to the United States had been affected.

Among them were tests provided to the Department of Defense for distribution to community health programmes.

In a statement dated October 1, the company said the voluntary recall was ordered after false positive results were reported in some product batches at higher rates than expected.

"I offer my sincere apologies -- and the apologies of our entire company -- for the stress or difficulties people may have experienced due to a false positive result," founder Sean Parsons said.

The firm said it had identified the cause of the issue and implemented additional controls, and had resumed distributing the tests to US retailers.

"We have and will continue to work diligently to ensure test accuracy, in all cases," Parsons added.

Comments

Comments are closed.